Birgit Schittek
YOU?
Author Swipe
View article: Commensal Staphylococci attenuate Staphylococcus aureus skin colonization and inflammation via AHR-dependent signaling
Commensal Staphylococci attenuate Staphylococcus aureus skin colonization and inflammation via AHR-dependent signaling Open
Introduction Staphylococcus aureus is the leading cause of bacterial skin infections in several inflammatory skin diseases, however, is rarely detected on healthy skin. Skin barrier defects, such as in atopic dermatitis, promote S. aureus …
View article: NOD2-Induced IκBζ Mediates a Protective Host Response against Epicutaneous Staphylococcus aureus Infection
NOD2-Induced IκBζ Mediates a Protective Host Response against Epicutaneous Staphylococcus aureus Infection Open
IκBζ, an atypical and largely unknown member of the IκB family, is a transcriptional coactivator of selective immune functions. In this study, we investigated the role of keratinocyte-derived IκBζ upon infection with a multidrug-resistant …
View article: Imaging gastric cancer metastasis progression in an organotypic, three-dimensional functional model of the human peritoneum
Imaging gastric cancer metastasis progression in an organotypic, three-dimensional functional model of the human peritoneum Open
Objectives Despite the introduction of multimodal treatment regimens, the prognosis of gastric cancer peritoneal metastasis (GCPM) remains poor. To establish efficient therapies, a deeper understanding of pathophysiological mechanisms in t…
View article: The microbiome-derived antibacterial lugdunin acts as a cation ionophore in synergy with host peptides
The microbiome-derived antibacterial lugdunin acts as a cation ionophore in synergy with host peptides Open
Lugdunin is a microbiome-derived antibacterial agent with good activity against Gram-positive pathogens in vitro and in animal models of nose colonization and skin infection. We have previously shown that lugdunin depletes bacterial energy…
View article: Lipase-mediated detoxification of host-derived antimicrobial fatty acids by Staphylococcus aureus
Lipase-mediated detoxification of host-derived antimicrobial fatty acids by Staphylococcus aureus Open
Long-chain fatty acids with antimicrobial properties are abundant on the skin and mucosal surfaces, where they are essential to restrict the proliferation of opportunistic pathogens such as Staphylococcus aureus . These antimicrobial fatty…
View article: <scp>PARP1</scp> expression predicts <scp>PARP</scp> inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma
<span>PARP1</span> expression predicts <span>PARP</span> inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma Open
Metastatic melanoma is still a difficult‐to‐treat cancer type owing to its frequent resistance mechanisms to targeted and immunotherapy. Therefore, we aimed to unravel novel therapeutic strategies for melanoma patients. Preclinical and cli…
View article: Dormancy of cutaneous melanoma
Dormancy of cutaneous melanoma Open
Many cancer-related deaths including melanoma result from metastases that develop months or years after the initial cancer therapy. Even the most effective drugs and immune therapies rarely eradicate all tumor cells. Instead, they strongly…
View article: Crosstalk between keratinocytes and neutrophils shapes skin immunity against S. aureus infection
Crosstalk between keratinocytes and neutrophils shapes skin immunity against S. aureus infection Open
Introduction Staphylococcus aureus ( S. aureus ) infection of the skin leads to a rapid initial innate immune response with keratinocytes in the epidermis as the initial sensors. Polymorphonuclear neutrophils (PMNs) are the first innate im…
View article: Histological and functional characterization of 3D human skin models mimicking the inflammatory skin diseases psoriasis and atopic dermatitis
Histological and functional characterization of 3D human skin models mimicking the inflammatory skin diseases psoriasis and atopic dermatitis Open
Three-dimensional (3D) human skin equivalents have emerged as valuable tools in skin research, replacing animal experimentation and precluding the need for patient biopsies. In this study, we advanced 3D skin equivalents to model the infla…
View article: FIGURE 4 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
FIGURE 4 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
Synthetic lethality elicits synergism in the combination of MAPKi with PARPi. MUH cell viability assay of A375 R or A375 RR cells treated with different concentrations of talazoparib (Tala.), vemurafenib (Vem.; A), trametinib (Trame.; B), …
View article: FIGURE 5 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
FIGURE 5 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
MAPKi induce HRD phenotype and thereby act synthetic lethal in combination with PARPi. A, Immunofluorescence of A375 S cells that were treated with 5 μmol/L talazoparib (Tala.), 5 μmol/L vemurafenib (Vem.), or a combination of both inhibit…
View article: Supplementary Figure 2 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 2 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
Synergistic interaction of PARPi and MAPKi treatment
View article: Supplementary Figure 2 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 2 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
Synergistic interaction of PARPi and MAPKi treatment
View article: Supplementary Figure 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
PARPi treatment in melanoma cells
View article: FIGURE 3 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
FIGURE 3 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
MAPKi resistant cells show decreased ATM expression. A, Immunoblot analysis of A375 R cells treated with 5 μmol/L talazoparib (Tala.) for 24 hours or untreated (Ctr.). Relative protein expression is shown. Actin control was reused from Fig…
View article: FIGURE 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
FIGURE 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
MAPKi resistant melanoma cells are highly susceptible to PARPi treatment. A, MUH cell viability assay of vemurafenib sensitive (S) and resistant (R) melanoma cell lines as well as PDX R cells treated with different concentrations of PARPi …
View article: FIGURE 2 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
FIGURE 2 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
PARPi treatment induces p53-associated proapoptotic genes and cell death in BRAFi resistant melanoma cells. A, Migration and Invasion assay using A375 R cells that were treated with 5 μmol/L talazoparib (Tala.) for 24 hours or remained unt…
View article: Supplementary Table 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
RT2 ProfilerTM PCR Array Human p53 Signaling Pathway and Human DNA Repair Pathway
View article: TABLE 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
TABLE 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
Primers used in this project
View article: TABLE 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
TABLE 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
Primers used in this project
View article: Supplementary Table 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
RT2 ProfilerTM PCR Array Human p53 Signaling Pathway and Human DNA Repair Pathway
View article: Supplementary Figure 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
PARPi treatment in melanoma cells
View article: FIGURE 5 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
FIGURE 5 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
MAPKi induce HRD phenotype and thereby act synthetic lethal in combination with PARPi. A, Immunofluorescence of A375 S cells that were treated with 5 μmol/L talazoparib (Tala.), 5 μmol/L vemurafenib (Vem.), or a combination of both inhibit…
View article: FIGURE 4 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
FIGURE 4 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
Synthetic lethality elicits synergism in the combination of MAPKi with PARPi. MUH cell viability assay of A375 R or A375 RR cells treated with different concentrations of talazoparib (Tala.), vemurafenib (Vem.; A), trametinib (Trame.; B), …
View article: FIGURE 3 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
FIGURE 3 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
MAPKi resistant cells show decreased ATM expression. A, Immunoblot analysis of A375 R cells treated with 5 μmol/L talazoparib (Tala.) for 24 hours or untreated (Ctr.). Relative protein expression is shown. Actin control was reused from Fig…
View article: FIGURE 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
FIGURE 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i> Open
MAPKi resistant melanoma cells are highly susceptible to PARPi treatment. A, MUH cell viability assay of vemurafenib sensitive (S) and resistant (R) melanoma cell lines as well as PDX R cells treated with different concentrations of PARPi …